Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Alstonine** is a plant-derived indole alkaloid, naturally occurring in various species such as *Alstonia boonei*, *Rauvolfia vomitoria*, and *Catharanthus roseus*.[1][5] It is a pentacyclic compound with putative antipsychotic activity, traditionally used in Nigerian herbal medicine for mental illnesses[3][7]. Preclinical studies indicate a potent antipsychotic profile, reducing hyperlocomotion, stereotypy, and social withdrawal in animal models, with additional anxiolytic-like, anticancer, and antimalarial effects[1][3][5][6][7][8]. Mechanistically, alstonine appears to modulate serotonergic (5-HT2A, 5-HT2C) and dopaminergic pathways, increasing serotonergic signaling and intraneuronal dopamine catabolism, with indications of serotonin receptor agonism and indirect glutamate uptake inhibition[7][5]. Alstonine lacks extrapyramidal or metabolic side effects typical of established antipsychotics in animal studies[7][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alstonine.